Concise review: Clinical translation of wound healing therapies based on mesenchymal stem cells

Stem Cells Translational Medicine

Volumn 1, Issue 1, 2012, Pages 44-50

  Jackson, Wesley M ^a   Nesti, Leon J ^a,b   Tuan, Rocky S ^c  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Clinical translation; Dermal regeneration; Diabetic ulcer; Immunomodulation; Preclinical research; Regenerative medicine; Tissue engineering

Indexed keywords

ADRENOMEDULLIN; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CYTOKINE; FIBRIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; PROSTAGLANDIN E2; SECONDARY LYMPHOID TISSUE CHEMOKINE; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); EPITHELIZATION; EXTRACELLULAR MATRIX; GRANULATION TISSUE; HUMAN; IN VIVO STUDY; INFLAMMATION; INJURY; KERATINOCYTE; MESENCHYMAL STEM CELL TRANSPLANTATION; NATURAL KILLER CELL; NONHUMAN; REVIEW; SYSTEMATIC REVIEW (TOPIC); TISSUE REGENERATION; VALIDATION PROCESS; WOUND CLOSURE; WOUND HEALING; ANGIOGENESIS; ANIMAL; ANIMAL MODEL; DIABETIC FOOT; PATHOLOGY; PATHOPHYSIOLOGY; REGENERATIVE MEDICINE; SKIN; TRANSLATIONAL RESEARCH; VASCULARIZATION;

ANIMALS; DIABETIC FOOT; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; REGENERATIVE MEDICINE; SKIN; TRANSLATIONAL MEDICAL RESEARCH; WOUND HEALING;

EID: 84872023663     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2011-0024     Document Type: Review

References (86)

1. Clark R. Wound repair overview and general considerations. In: Clark R, ed. The Molecular and Cellular Biology of Wound Repair. New York, NY: Plenum Press, 1996:3-50.
2. Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 2005;1:100-110.
3. Salem HK, Thiemermann C. Mesenchymal stromal cells: Current understanding and clinical status. STEM CELLS 2010;28:585-596.
4. Badiavas EV, Abedi M, Butmarc J et al. Participation of bone marrow derived cells in cutaneous wound healing. J Cell Physiol 2003; 196:245-250.
5. Jackson WM, Nesti LJ, Tuan RS. Mesenchymal stem cell therapy for attenuation of scar formation during wound healing. Stem Cell Res Ther 2012 (in press).
6. Martin P. Wound healing: Aiming for perfect skin regeneration. Science 1997;276:75-81.
7. Velnar T, Bailey T, Smrkolj V. The wound healing process: An overview of the cellular and molecular mechanisms. J Int Med Res 2009;37:1528-1542.
8. Arnout J, Hoylaerts MF, Lijnen HR. Haemostasis. Handb Exp Pharmacol. 2006;(176):1-41.
9. Barrientos S, Stojadinovic O, Golinko MS et al. Growth factors and cytokines in wound healing. Wound Repair Regen 2008;16:585-601.
10. Diegelmann RF, Evans MC. Wound healing: An overview of acute, fibrotic and delayed healing. Front Biosci 2004;9:283-289.
11. Abe R, Donnelly SC, Peng T et al. Peripheral blood fibrocytes: Differentiation pathway and migration to wound sites. J Immunol 2001; 166:7556-7562.
12. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007;87:858-870.
13. Friedenstein AJ, Deriglasova UF, Kulagina NN et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974;2:83-92.
14. Gimble JM, Guilak F. Adipose-derived adult stem cells: Isolation, characterization, and differentiation potential. Cytotherapy 2003;5:362-369.
15. Meliga E, Strem BM, Duckers HJ et al. Adipose-derived cells. Cell Transplant 2007;16: 963-970.
16. Jones EA, English A, Henshaw K et al. Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. Arthritis Rheum 2004;50:817-827.
17. Vandenabeele F, De Bari C, Moreels M et al. Morphological and immunocytochemical characterization of cultured fibroblast-like cells derived from adult human synovial membrane. Arch Histol Cytol 2003;66:145-153.
18. Fan J, Varshney RR, Ren L et al. Synovium-derived mesenchymal stem cells: A new cell source for musculoskeletal regeneration. Tissue Eng Part B 2009;15:75-86.
19. Nesti LJ, Jackson WM, Shanti RM et al. Differentiation potential of multipotent progenitor cells derived from war-traumatized muscle tissue. J Bone Joint Surg Am 2008;90: 2390-2398.
20. Jackson WM, Aragon AB, Djouad F et al. Mesenchymal progenitor cells derived from traumatized human muscle. J Tissue Eng Regen Med 2009;3:129-138.
21. De Coppi P, Bartsch G, Jr., Siddiqui MM et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007;25: 100-106.
22. Weiss ML, Troyer DL. Stem cells in the umbilical cord. Stem Cell Rev 2006;2:155-162.
23. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317.
24. Caplan AI. All MSCs are pericytes? Cell Stem Cell 2008;3:229-230.
25. Caplan AI. Why are MSCs therapeutic? New data: New insight. J Pathol 2009;217: 318-324.
26. Crisan M, Yap S, Casteilla L et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3:301-313.
27. Hemeda H, Jakob M, Ludwig AK et al. Interferon-and tumor necrosis factor-÷ differentially affect cytokine expression and migration properties of mesenchymal stem cells. Stem Cells Dev 2010;19:693-706.
28. Mishima Y, Lotz M. Chemotaxis of human articular chondrocytes and mesenchymal stem cells. J Orthop Res 2008;26:1407-1412.
29. Ortiz LA, Gambelli F, McBride C et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003;100:8407-8411.
30. Chen L, Tredget EE, Liu C et al. Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice. PLoS One 2009;4:e7119.
31. Ponte AL, Marais E, Gallay N et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities. STEM CELLS 2007;25:1737-1745.
32. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2:141-150.
33. Brown JM, Nemeth K, Kushnir-Sukhov NM et al. Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin Exp Allergy 2011;41:526-534.
34. Djouad F, Bouffi C, Ghannam S et al. Mesenchymal stem cells: Innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 2009;5:392-399.
35. Corcione A, Benvenuto F, Ferretti E et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367-372.
36. Sotiropoulou P, Perez S, Gritzapis A et al. Interactions between human mesenchymal stem cells and natural killer cells. STEM CELLS 2006;24:74-85.
37. Németh K, Leelahavanichkul A, Yuen PS et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009;15:42-49.
38. Djouad F, Charbonnier LM, Bouffi C et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. STEM CELLS 2007;25: 2025-2032.
39. Jarvinen L, Badri L, Wettlaufer S et al. Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. J Immunol 2008;181:4389-4396.
40. Aggarwal S, Pittenger M. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822.
41. Benbernou N, Esnault S, Shin HC et al. Differential regulation of IFN-, IL-10 and inducible nitric oxide synthase in human T cells by cyclic AMP-dependent signal transduction pathway. Immunology 1997;91:361-368.
42. Reitamo S, Remitz A, Tamai K et al. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest 1994;94: 2489-2492.
43. Jeon YK, Jang YH, Yoo DR et al. Mesenchymal stem cells' interaction with skin: Wound-healing effect on fibroblast cells and skin tissue. Wound Repair Regen 2010;18:655-661.
44. Peranteau WH, Zhang L, Muvarak N et al. IL-10 overexpression decreases inflammatory mediators and promotes regenerative healing in an adult model of scar formation. J Invest Dermatol 2008;128:1852-1860.
45. Renault MA, Roncalli J, Tongers J et al. The Hedgehog transcription factor Gli3 modulates angiogenesis. Circ Res 2009;105:818-826.
46. Gruber R, Kandler B, Holzmann P et al. Bone marrow stromal cells can provide a local environment that favors migration and formation of tubular structures of endothelial cells. Tissue Eng 2005;11:896-903.
47. Kaigler D, Krebsbach PH, Polverini PJ et al. Role of vascular endothelial growth factor in bone marrow stromal cell modulation of endothelial cells. Tissue Eng 2003;9:95-103.
48. Lozito TP, Taboas JM, Kuo CK et al. Mesenchymal stem cell modification of endothelial matrix regulates their vascular differentiation. J Cell Biochem 2009;107:706-713.
49. Kato J, Tsuruda T, Kita T et al. Adrenomedullin: A protective factor for blood vessels. Arterioscler Thromb Vasc Biol 2005;25: 2480-2487.
50. Au P, Tam J, Fukumura D et al. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 2008;111:4551-4558.
51. Li L, Zhang Y, Li Y et al. Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. Transpl Int 2008;21:1181-1189.
52. Chen L, Tredget EE, Wu PY et al. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008;3: e1886.
53. Kim CH, Lee JH, Won JH et al. Mesenchymal stem cells improve wound healing in vivo via early activation of matrix metalloproteinase-9 and vascular endothelial growth factor. J Korean Med Sci 2011;26:726-733.
54. Schievenbusch S, Strack I, Scheffler M et al. Profiling of anti-fibrotic signaling by hepatocyte growth factor in renal fibroblasts. Biochem Biophys Res Commun 2009;385:55-61.
55. Mou S, Wang Q, Shi B et al. Hepatocyte growth factor suppresses transforming growth factor--1 and type III collagen in human primary renal fibroblasts. Kaohsiung J Med Sci 2009;25:577-587.
56. Kanemura H, Iimuro Y, Takeuchi M et al. Hepatocyte growth factor gene transfer with naked plasmid DNA ameliorates dimethylnitrosamine-induced liver fibrosis in rats. Hepatol Res 2008;38:930-939.
57. Bevan D, Gherardi E, Fan TP et al. Diverse and potent activities of HGF/SF in skin wound repair. J Pathol 2004;203:831-838.
58. Shukla MN, Rose JL, Ray R et al. Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7. Am J Respir Cell Mol Biol 2009;40:643-653.
59. McAnulty RJ. Fibroblasts and myofibro-blasts: Their source, function and role in disease. Int J Biochem Cell Biol 2007;39:666-671.
60. Opalenik SR, Davidson JM. Fibroblast differentiation of bone marrow-derived cells during wound repair. FASEB J 2005;19:1561-1563.
61. Bucala R, Spiegel LA, Chesney J et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994;1:71-81.
62. Yang J, Dai C, Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol 2005;16:68-78.
63. Zhang A, Wang MH, Dong Z et al. Prostaglandin E2 is a potent inhibitor of epithelial-tomesenchymal transition: Interaction with hepatocyte growth factor. Am J Physiol Renal Physiol 2006;291:F1323-F1331.
64. Smith AN, Willis E, Chan VT et al. Mesenchymal stem cells induce dermal fibroblast responses to injury. Exp Cell Res 2010;316:48-54.
65. Fu X, Fang L, Li X et al. Enhanced woundhealing quality with bone marrow mesenchymal stem cells autografting after skin injury. Wound Repair Regen 2006;14:325-335.
66. Sasaki M, Abe R, Fujita Y et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol 2008;180:2581-2587.
67. Jin G, Prabhakaran MP, Ramakrishna S. Stem cell differentiation to epidermal lineages on electrospun nanofibrous substrates for skin tissue engineering. Acta Biomater 2011;7: 3113-3122.
68. Wu Y, Chen L, Scott PG et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. STEM CELLS 2007;25:2648-2659.
69. Yang JA, Chung HM, Won CH et al. Potential application of adipose-derived stem cells and their secretory factors to skin: Discussion from both clinical and industrial viewpoints. Expert Opin Biol Ther 2010;10:495-503.
70. Mansilla E, Marin GH, Sturla F et al. Human mesenchymal stem cells are tolerized by mice and improve skin and spinal cord injuries. Transplant Proc 2005;37:292-294.
71. Ryan JM, Barry FP, Murphy JM et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005;2:8.
72. Nie C, Yang D, Xu J et al. Locally administered adipose-derived stem cells accelerate wound healing through differentiation and vasculogenesis. Cell Transplant. 2011;20:205-216.
73. Stoff A, Rivera AA, Banerjee NS et al. Promotion of incisional wound repair by human mesenchymal stem cell transplantation. Exp Dermatol 2009;18:362-369.
74. Javazon EH, Keswani SG, Badillo AT et al. Enhanced epithelial gap closure and increased angiogenesis in wounds of diabetic mice treated with adult murine bone marrow stromal progenitor cells. Wound Repair Regen 2007;15:350-359.
75. Maharlooei MK, Bagheri M, Solhjou Z et al. Adipose tissue derived mesenchymal stem cell (AD-MSC) promotes skin wound healing in diabetic rats. Diabetes Res Clin Pract 2011;93: 228-234.
76. Mansilla E, Spretz R, Larsen G et al. Outstanding survival and regeneration process by the use of intelligent acellular dermal matrices and mesenchymal stem cells in a burn pig model. Transplant Proc 2010;42:4275-4278.
77. Egaña JT, Fierro FA, Kruger S et al. Use of human mesenchymal cells to improve vascularization in a mouse model for scaffold-based dermal regeneration. Tissue Eng Part A 2009; 15:1191-1200.
78. Ma K, Liao S, He L et al. Effects of nano-fiber/stem cell composite on wound healing in acute full-thickness skin wounds. Tissue Eng Part A 2011;17:1413-1424.
79. Falanga V, Iwamoto S, Chartier M et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007;13:1299-1312.
80. McFarlin K, Gao X, Liu YB et al. Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat. Wound Repair Regen 2006;14:471-478.
81. Yoshikawa T, Mitsuno H, Nonaka I et al. Wound therapy by marrow mesenchymal cell transplantation. Plast Reconstr Surg 2008;121: 860-877.
82. Clinical Trials.gov. Available at http://www.clinicaltrials.gov. Accessed August 29, 2011.
83. Sorrell JM, Caplan AI. Topical delivery of mesenchymal stem cells and their function in wounds. Stem Cell Res Ther 2010;1:30.
84. Schurr MJ, Foster KN, Centanni JM et al. Phase I/II clinical evaluation of StrataGraft: A consistent, pathogen-free human skin substitute. J Trauma 2009;66:866-873, discussion 873-864.
85. Gerlach JC, Johnen C, McCoy E et al. Autologous skin cell spray-transplantation for a deep dermal burn patient in an ambulant treatment room setting. Burns 2011;37:e19-e23.
86. Gravante G, Di Fede MC, Araco A et al. A randomized trial comparing ReCell system of epidermal cells delivery versus classic skin grafts for the treatment of deep partial thickness burns. Burns 2007;33:966-972.